Home › Compare › KARBF vs ORCC
KARBF yields 38.10% · ORCC yields 9.79%● Live data
📍 KARBF pulled ahead of the other in Year 1
Combined, KARBF + ORCC cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KARBF + ORCC for your $10,000?
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands. It sells its products in approximately 90 countries with Europe and the Nordic region markets through direct sales organizations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is headquartered in Stockholm, Sweden.
Full KARBF Calculator →Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.
Full ORCC Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.